Epstein-Barr virus latent membrane protein 1 and 2-derived peptide–human leukocyte antigen complex (LMP1/2-peptide-HLA complex)

The Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) and 2 (LMP2) are viral oncogenes expressed during the latent phase of EBV infection, particularly in Latency II and III programs. LMP1 acts as a constitutively active mimic of the CD40 receptor, while LMP2A mimics the B-cell receptor, both of which drive cell survival and proliferation in infected cells (PMID: 25406351). These proteins are processed into short peptides and presented on the cell surface by Human Leukocyte Antigen (HLA) molecules, forming peptide-HLA complexes that are recognized by the T-cell receptors (TCRs) of CD8+ cytotoxic T cells. In EBV-associated malignancies such as nasopharyngeal carcinoma and post-transplant lymphoproliferative disorder (PTLD), these complexes serve as highly specific targets for immunotherapies, including adoptive T-cell transfers and TCR-engineered T cells (PMID: 31435467). Because these targets are of viral origin, they offer a high degree of tumor specificity, potentially minimizing damage to healthy, non-infected tissues. However, therapeutic efficacy can be limited by the downregulation of HLA molecules by tumor cells or the presence of an immunosuppressive tumor microenvironment (PMID: 29147111).

Other names

EBV LMP1/2-MHC complexLMP1/2-HLA complexEpstein-Barr virus latent membrane protein peptide-HLA complexesLMP1/2-derived pMHC

Recognition of the specific viral peptide-HLA complex by T-cell receptors (TCRs) or TCR-like antibodies, leading to targeted cytotoxic T-lymphocyte (CTL) mediated lysis of EBV-infected cells.